CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

Polly D. Gregor; Jedd D. Wolchok; Cristina R. Ferrone; Heidi Buchinshky; Jose A. Guevara-Patiño; Miguel Angel Perales; Fariborz Mortazavi; Dean Bacich; Warren Heston; Jean Baptiste Latouche; Michel Sadelain; James P. Allison; Howard I. Scher; Alan N. Houghton

doi:10.1016/j.vaccine.2003.10.048

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

Polly D. Gregor, Jedd D. Wolchok, Cristina R. Ferrone, Heidi Buchinshky, Jose A. Guevara-Patiño, Miguel Angel Perales, Fariborz Mortazavi, Dean Bacich, Warren Heston, Jean Baptiste Latouche, Michel Sadelain, James P. Allison, Howard I. Scher, Alan N. Houghton

Research output: Contribution to journal › Article › peer-review

115 Scopus citations

Abstract

Xenogeneic DNA vaccination can elicit tumor immunity through T cell and antibody-dependent effector mechanisms. Blockade of CTLA-4 engagement with B7 expressed on APCs has been shown to enhance T cell-dependent immunity. We investigated whether CTLA-4 blockade could increase T-cell responses and tumor immunity elicited by DNA vaccines. CTLA-4 blockade enhanced B16 tumor rejection in mice immunized against the melanoma differentiation antigens tyrosinase-related protein 2 and gp100, and this effect was stronger when anti-CTLA-4 was administered with booster vaccinations. CTLA-4 blockade also increased the T-cell responses to prostate-specific membrane antigen (PSMA) when given with the second or third vaccination. Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration.

Original language	English (US)
Pages (from-to)	1700-1708
Number of pages	9
Journal	Vaccine
Volume	22
Issue number	13-14
DOIs	https://doi.org/10.1016/j.vaccine.2003.10.048
State	Published - Apr 16 2004
Externally published	Yes

Keywords

CTLA-4
DNA vaccine
Tumor immunity

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2003.10.048

Cite this

Gregor, P. D., Wolchok, J. D., Ferrone, C. R., Buchinshky, H., Guevara-Patiño, J. A., Perales, M. A., Mortazavi, F., Bacich, D., Heston, W., Latouche, J. B., Sadelain, M., Allison, J. P., Scher, H. I., & Houghton, A. N. (2004). CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine, 22(13-14), 1700-1708. https://doi.org/10.1016/j.vaccine.2003.10.048

Gregor, PD, Wolchok, JD, Ferrone, CR, Buchinshky, H, Guevara-Patiño, JA, Perales, MA, Mortazavi, F, Bacich, D, Heston, W, Latouche, JB, Sadelain, M, Allison, JP, Scher, HI & Houghton, AN 2004, 'CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems', Vaccine, vol. 22, no. 13-14, pp. 1700-1708. https://doi.org/10.1016/j.vaccine.2003.10.048

@article{ab0473e4d1de4a0faa9c02920cec9cdc,

title = "CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems",

abstract = "Xenogeneic DNA vaccination can elicit tumor immunity through T cell and antibody-dependent effector mechanisms. Blockade of CTLA-4 engagement with B7 expressed on APCs has been shown to enhance T cell-dependent immunity. We investigated whether CTLA-4 blockade could increase T-cell responses and tumor immunity elicited by DNA vaccines. CTLA-4 blockade enhanced B16 tumor rejection in mice immunized against the melanoma differentiation antigens tyrosinase-related protein 2 and gp100, and this effect was stronger when anti-CTLA-4 was administered with booster vaccinations. CTLA-4 blockade also increased the T-cell responses to prostate-specific membrane antigen (PSMA) when given with the second or third vaccination. Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration.",

keywords = "CTLA-4, DNA vaccine, Tumor immunity",

author = "Gregor, {Polly D.} and Wolchok, {Jedd D.} and Ferrone, {Cristina R.} and Heidi Buchinshky and Guevara-Pati{\~n}o, {Jose A.} and Perales, {Miguel Angel} and Fariborz Mortazavi and Dean Bacich and Warren Heston and Latouche, {Jean Baptiste} and Michel Sadelain and Allison, {James P.} and Scher, {Howard I.} and Houghton, {Alan N.}",

note = "Funding Information: This work has been supported by Swim Across America, the MSKCC SPORE in Prostate cancer (P50 CA92629)(P.D.G., J.D.W., H.I.S. and A.N.H.), CapCURE (P.D.G. and J.D.W.), PepsiCo (P.D.G., J.D.W. and A.N.H.), R01 CA56821 (A.N.H.), NIH DK47650 (W.H. and D.B.), Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Cancer Foundation for Research and the Experimental Therapeutics Center of MSKCC (M.A.P., J.G.-P., and A.N.H.), PO1 CA59350 and P30 CA08748 (J.-B.L. and M.S.), and the Quentin J. Kennedy Family Fund (F.M. and J.D.W.). ",

year = "2004",

month = apr,

day = "16",

doi = "10.1016/j.vaccine.2003.10.048",

language = "English (US)",

volume = "22",

pages = "1700--1708",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "13-14",

}

TY - JOUR

T1 - CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

AU - Gregor, Polly D.

AU - Wolchok, Jedd D.

AU - Ferrone, Cristina R.

AU - Buchinshky, Heidi

AU - Guevara-Patiño, Jose A.

AU - Perales, Miguel Angel

AU - Mortazavi, Fariborz

AU - Bacich, Dean

AU - Heston, Warren

AU - Latouche, Jean Baptiste

AU - Sadelain, Michel

AU - Allison, James P.

AU - Scher, Howard I.

AU - Houghton, Alan N.

N1 - Funding Information: This work has been supported by Swim Across America, the MSKCC SPORE in Prostate cancer (P50 CA92629)(P.D.G., J.D.W., H.I.S. and A.N.H.), CapCURE (P.D.G. and J.D.W.), PepsiCo (P.D.G., J.D.W. and A.N.H.), R01 CA56821 (A.N.H.), NIH DK47650 (W.H. and D.B.), Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Cancer Foundation for Research and the Experimental Therapeutics Center of MSKCC (M.A.P., J.G.-P., and A.N.H.), PO1 CA59350 and P30 CA08748 (J.-B.L. and M.S.), and the Quentin J. Kennedy Family Fund (F.M. and J.D.W.).

PY - 2004/4/16

Y1 - 2004/4/16

N2 - Xenogeneic DNA vaccination can elicit tumor immunity through T cell and antibody-dependent effector mechanisms. Blockade of CTLA-4 engagement with B7 expressed on APCs has been shown to enhance T cell-dependent immunity. We investigated whether CTLA-4 blockade could increase T-cell responses and tumor immunity elicited by DNA vaccines. CTLA-4 blockade enhanced B16 tumor rejection in mice immunized against the melanoma differentiation antigens tyrosinase-related protein 2 and gp100, and this effect was stronger when anti-CTLA-4 was administered with booster vaccinations. CTLA-4 blockade also increased the T-cell responses to prostate-specific membrane antigen (PSMA) when given with the second or third vaccination. Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration.

AB - Xenogeneic DNA vaccination can elicit tumor immunity through T cell and antibody-dependent effector mechanisms. Blockade of CTLA-4 engagement with B7 expressed on APCs has been shown to enhance T cell-dependent immunity. We investigated whether CTLA-4 blockade could increase T-cell responses and tumor immunity elicited by DNA vaccines. CTLA-4 blockade enhanced B16 tumor rejection in mice immunized against the melanoma differentiation antigens tyrosinase-related protein 2 and gp100, and this effect was stronger when anti-CTLA-4 was administered with booster vaccinations. CTLA-4 blockade also increased the T-cell responses to prostate-specific membrane antigen (PSMA) when given with the second or third vaccination. Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration.

KW - CTLA-4

KW - DNA vaccine

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=11144353596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144353596&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2003.10.048

DO - 10.1016/j.vaccine.2003.10.048

M3 - Article

C2 - 15068853

AN - SCOPUS:11144353596

SN - 0264-410X

VL - 22

SP - 1700

EP - 1708

JO - Vaccine

JF - Vaccine

IS - 13-14

ER -

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this